公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC | Tan W.L.; Chua K.L.M.; CHIA-CHI LIN ; Lee V.H.F.; Tho L.M.; Chan A.W.; Ho G.F.; Reungwetwattana T.; YCHIH-HSIN YANG ; Kim D.-W.; Soo R.A.; Ahn Y.C.; Onishi H.; Ahn M.-J.; Mok T.S.K.; Tan D.S.W.; Yang F. | Journal of Thoracic Oncology | 33 | 30 | |
2011 | Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS) | Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG ; Mok T.S.K. | Journal of Clinical Oncology | 1256 | 1128 | |
2015 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 | CHIH-HSIN YANG ; Sequist L.V.; Geater S.L.; Tsai C.-M.; Mok T.S.K.; Schuler M.; Yamamoto N.; CHONG-JEN YU ; Ou S.H.I.; Zhou C.; Massey D.; Zazulina V.; Wu Y.-L. | The Lancet Oncology | 778 | 644 | |
2021 | Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis | Kok P.-S.; Lee K.; Lord S.; CHIH-HSIN YANG ; Rosell R.; Goto K.; John T.; Wu Y.-L.; Mok T.S.K.; Lee C.K. | Lung Cancer | 4 | 4 | |
2021 | Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial | CHIH-HSIN YANG ; Mok T.S.K.; Lu S.; Nakagawa K.; Yamamoto N.; Shi Y.-K.; Zhang L.; Soo R.A.; Morita S.; Tamura T. | JTO Clinical and Research Reports | 0 | 0 | |
2014 | Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III iressa pan-ASia study (IPASS) | CHIH-HSIN YANG ; Wu Y.-L; Chan V; Kurnianda J; Nakagawa K; Saijo N; Fukuoka M; McWalter G; McCormack R; Mok T.S.K. | Lung Cancer | 39 | 35 | |
2015 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial | Soria J.-C; Wu Y.-L; Nakagawa K; Kim S.-W; CHIH-HSIN YANG ; Ahn M.-J; Wang J; Lu Y; Atagi S; Ponce S; Lee D.H; Liu Y; Yoh K; Zhou J.-Y; Shi X; Webster A; Jiang H; Mok T.S.K. | The Lancet Oncology | 353 | 315 | |
2009 | Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer | Mok T.S.K.; Wu Y.-L.; CHONG-JEN YU ; Zhou C.; Chen Y.-M.; Zhang L.; Ignacio J.; Liao M.; Srimuninnimit V.; Boyer M.J.; Chua-Tan M.; Sriuranpong V.; Sudoyo A.W.; Jin K.; Johnston M.; Chui W.; Lee J.-S. | Journal of Clinical Oncology | 207 | 178 | |
2017 | Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry | Gautschi O.; Milia J.; Filleron T.; Wolf J.; Carbone D.P.; Owen D.; Camidge R.; Narayanan V.; Doebele R.C.; Besse B.; Remon-Masip J.; Janne P.A.; Awad M.M.; Peled N.; Byoung C.-C.; Karp D.D.; Van Den Heuvel M.; Wakelee H.A.; Neal J.W.; Mok T.S.K.; CHIH-HSIN YANG ; Ou S.-H.I.; Pall G.; Froesch P.; Zalcman G.; Gandara D.R.; Riess J.W.; Velcheti V.; Zeidler K.; Diebold J.; Früh M.; Michels S.; Monnet I.; Popat S.; Rosell R.; Karachaliou N.; Rothschild S.I.; JIN-YUAN SHIH ; Warth A.; Muley T.; Cabillic F.; Mazières J.; Drilon A. | Journal of Clinical Oncology | 279 | 249 |